Vertex Pharmaceuticals Raises 2026 Revenue Guidance Following Q3 Results
Vertex Pharmaceuticals (VRTX) reported third-quarter financial results characterized by a top-line beat alongside a bottom-line miss. Despite the mixed quarterly performance, the company has proactively increased its revenue guidance for 2026. The updated full-year revenue projection now sits between $13.15 billion and $13.25 billion, an increase from the previous range of $13.1 billion to $13.2 billion. This new guidance remains closely aligned with market consensus expectations of approximately $13.28 billion.
Tickers: $VRTX
Topics: financial results quarterly earnings revenue guidance